Welcome to our dedicated page for CARDINAL HEALTH SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardinal Health, Inc. filings document material events for a healthcare distribution and medical products company, including quarterly results, Regulation FD outlook updates and earnings presentation exhibits. The records tie financial reporting to segment performance, capital returns, debt reduction and corporate finance matters such as revolving credit agreements that support the commercial paper program.
Governance filings cover board composition, annual meeting voting results, director and officer transitions, and related compensation or succession disclosures. The company’s 8-K record also includes material definitive agreements, shareholder voting matters, financial covenants, exhibits and other capital-structure disclosures for Cardinal Health’s public-company profile.
Mayer Jessica L reported acquisition or exercise transactions in this Form 4 filing.
Cardinal Health executive Jessica L. Mayer, Chief Legal/Compliance Officer, reported an equity grant of 46,992 Common Shares on August 4, 2026, at $0.00 per share. A footnote states these represent performance share units that will settle on August 15, 2026, bringing her reported direct holdings to 81,419 shares.
Mason Stephen M reported acquisition or exercise transactions in this Form 4 filing.
Cardinal Health executive Stephen M. Mason, CEO of the GMPD segment, received a grant of 46,992 performance share units on August 4, 2026, reported as common shares and described as units that will settle on August 15, 2026. This equity award, with no cash price per share, brings his directly held common shares to 72,482 and was not made under a Rule 10b5-1 trading plan.
WEITZMAN DEBORAH reported acquisition or exercise transactions in this Form 4 filing.
Cardinal Health executive Deborah Weitzman, CEO of the Pharmaceutical & Specialty Solutions segment, received an equity compensation award of 54,823 performance share units on August 4, 2026. These units represent rights to receive common shares and are scheduled to settle on August 15, 2026.
Following this grant, her reported direct holdings in Cardinal Health common shares increased to 107,700 shares. The award was recorded at a price of $0.0000 per share, reflecting that it was a compensation grant rather than an open‑market purchase.
Alt Aaron E reported acquisition or exercise transactions in this Form 4 filing.
CARDINAL HEALTH INC reported that Chief Financial Officer Aaron E. Alt received an equity award of 58,738 Common Shares in the form of performance share units on August 4, 2026. The award was granted at $0.0000 per share and will settle on August 15, 2026. Following this award, Alt directly holds 85,146 Common Shares.
Greene Michelle D. reported acquisition or exercise transactions in this Form 4 filing.
Cardinal Health Inc reported that Chief Information Officer Michelle D. Greene received a grant of 17,230 common shares in the form of performance share units that will settle on August 15, 2026. Following this award, she directly holds 29,460 common shares. The award carried no cash purchase price.
Cardinal Health Inc. Chief Executive Officer Jason M. Hollar reported an equity award. On August 4, 2026, he received 187,965 common shares at no cost, reported as a grant, award, or other acquisition. A footnote states the award reflects performance share units that will settle on August 15, 2026. Following this award, his directly held common shares position was 387,965.
Cardinal Health, Inc. appointed Anita Zielinski as Chief Accounting Officer, effective November 5, 2026. She will join as Senior Vice President Finance on September 16 and succeed Mary Scherer, who will remain Chief Accounting Officer through November 5, 2026.
Zielinski, 52, previously held senior finance and accounting roles at Baxter International and Sysco, and was a partner at Ernst & Young. Her compensation includes an annual base salary, annual cash bonus under the Management Incentive Plan, equity under the long-term incentive program, a $750,000 cash sign-on bonus, and an initial grant of time-vesting restricted share units with a grant date value of $1,000,000 that vest ratably over three years.
Cardinal Health reported strong growth for the quarter ended March 31, 2026. Revenue rose 11% to $60.9 billion, driven mainly by higher branded and specialty pharmaceutical sales, including increased GLP‑1 demand. Pharma segment revenue reached $56.1 billion, while Other grew 31% on at‑Home Solutions, Nuclear and Precision Health, and OptiFreight®.
GAAP operating earnings fell 30% to $509 million due to a $184 million goodwill impairment at the Navista & ION oncology MSO unit and the absence of prior‑year litigation recoveries. However, non‑GAAP operating earnings rose 18% to $956 million, and non‑GAAP diluted EPS increased 35% to $3.17, reflecting acquisitions of MSO platforms and Advanced Diabetes Supply Group and a strong generics program.
The company completed the $1.9 billion Solaris Health acquisition, helping lift goodwill to $11.4 billion, and ended the period with $3.9 billion of cash and equivalents. Liquidity is supported by unused credit facilities and a receivables program, while Cardinal continues making opioid settlement payments and investing in share repurchases and dividends. Tariffs remain a headwind, particularly in Global Medical Products and Distribution, where segment profit for the quarter declined 36%.
Cardinal Health reported a strong third quarter of fiscal 2026, combining solid growth with a notable non-cash charge. Revenue rose 11% to $60.9 billion versus the prior-year quarter. Non-GAAP operating earnings increased 18% to $956 million and non-GAAP diluted EPS grew 35% to $3.17, helped by stronger segment performance, a lower non-GAAP tax rate and a lower share count.
GAAP results were weaker as operating earnings fell 30% to $509 million and diluted EPS declined 20% to $1.69, driven mainly by a $184 million goodwill impairment in the Navista & ION reporting unit. The Pharmaceutical and Specialty Solutions segment posted 11% revenue growth and 18% profit growth, while the Other segment grew revenue 31% and profit 34%. Cardinal Health raised its fiscal 2026 non-GAAP EPS outlook to $10.70–$10.80, implying 30%–31% growth, and lifted adjusted free cash flow guidance to $3.3–$3.7 billion. The company also reduced debt, brought its leverage ratio to 3.0x and completed $1.0 billion of share repurchases year-to-date.